0%

est. 2Y upside i

HealthcareSeries B

Rank

#2282

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Low

Due to missing revenue and growth data, the equity upside cannot be reliably quantified.

Last updated: July 3, 2026

Bull (10%)0%

Strong moat and large TAM drive adoption; IPO window opens. Upside cannot be quantified without revenue data.

Base (55%)0%

Moderate growth; valuation converges to public comps. Cannot compute due to missing revenue.

Bear (35%)0%

Incumbent PBMs block growth; exit below total funding leads to -100% common recovery.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

3330%

Total funding of $100M implies a 33% preference overhang vs valuation of $301M, meaning common stock only participates above $100M.

Dilution Risk

moderate

Series B round closed 7 months ago; further raises likely within 2-3 years, diluting common holders by 15-25%.

Secondary Liquidity

limited

Secondary market exists (implied value $301M) but volume and frequency unknown; limited exit options for employees before a liquidity event.

View all 19 open roles at House Rx →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on House Rx's data — designed to show you've done your homework.

  • 1

    “What is the current annual recurring revenue and growth trajectory?”

  • 2

    “How do you intend to overcome PBM incumbent threats and regulatory barriers?”

  • 3

    “What is the expected timeline to liquidity and how does the employee equity stack rank relative to preferred?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.